Impact of Medication Education on Adherence and Side Effects

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorCumhuriyet University

About this trial

Severe mental disorders such as schizophrenia, bipolar disorder, and psychotic depression often require long-term or lifelong medication treatment. However, many psychiatric patients have difficulty adhering to their prescribed medication regimens due to factors such as lack of information, fear of side effects, and negative experiences with psychotropic medications. Poor treatment adherence is associated with symptom relapse, prolonged hospitalization, increased rehospitalization rates, reduced quality of life, and higher health care costs.

Medication education is a key psychosocial intervention aimed at improving patients' understanding of their illness, treatment process, and potential medication side effects. Providing structured medication education may enhance treatment adherence and help patients recognize and manage side effects more effectively.

This intervention study aims to evaluate the effect of a structured medication education program on treatment adherence and medication-related side effects among psychotic inpatients hospitalized in a psychiatric clinic, including patients diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar disorder with psychotic features, and major depressive disorder with psychotic features. The findings of this study are expected to contribute to the development of effective psychosocial interventions to improve medication adherence and treatment outcomes in psychiatric inpatient settings.

Eligibility criteria

Qualifiers

Adults aged 18-65 years

Hospitalized in a psychiatric inpatient clinic

Diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar disorder with psychotic features, or major depressive disorder with psychotic features

Receiving psychotropic medication treatment

Disqualifiers

Presence of severe cognitive impairment or intellectual disability

Acute medical or neurological conditions that may interfere with participation

Severe agitation or acute psychotic symptoms preventing participation

Hearing or communication impairments that limit participation in educational sessions

Trial design

Treatments tested in this trial

  • Medication Education Program
  • Routine Psychiatric Inpatient Care

Treatment groups

64 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators